Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NP137 |
Synonyms | |
Therapy Description |
NP137 is a humanized monoclonal antibody against netrin-1, which blocks netrin-1 binding to its receptors, potentially leads to dependence receptor (DR)-induced apoptosis (Cancer Res 2015;75(15 Suppl):Abstract nr 2921). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NP137 | NP 137|NP-137 | NP137 is a humanized monoclonal antibody against netrin-1, which blocks netrin-1 binding to its receptors, potentially leads to dependence receptor (DR)-induced apoptosis (Cancer Res 2015;75(15 Suppl):Abstract nr 2921). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02977195 | Phase I | NP137 | First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors (NP137) | Completed | FRA | 0 |
NCT06203821 | Phase I | NP137 Fluorouracil + Irinotecan + Leucovorin + NP137 + Oxaliplatin | Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer | Not yet recruiting | USA | 0 |